vs
Side-by-side financial comparison of ACHIEVE LIFE SCIENCES, INC. (ACHV) and Celldex Therapeutics, Inc. (CLDX). Click either name above to swap in a different company.
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops targeted immunotherapies for hard-to-treat cancers and rare immunological diseases. Its pipeline covers antibody-drug conjugates, monoclonal antibodies and other novel therapies, serving patients with high unmet medical needs mainly across North America and Europe.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $120.0K | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $730.0K | ||
| Q1 25 | — | $695.0K | ||
| Q4 24 | — | $1.2M | ||
| Q3 24 | — | $3.2M | ||
| Q2 24 | — | $2.5M | ||
| Q1 24 | — | $156.0K |
| Q4 25 | — | $-81.3M | ||
| Q3 25 | — | $-67.0M | ||
| Q2 25 | — | $-56.6M | ||
| Q1 25 | — | $-53.8M | ||
| Q4 24 | — | $-47.1M | ||
| Q3 24 | — | $-42.1M | ||
| Q2 24 | — | $-35.8M | ||
| Q1 24 | — | $-32.8M |
| Q4 25 | — | -72628.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -8747.5% | ||
| Q1 25 | — | -9027.2% | ||
| Q4 24 | — | -4768.3% | ||
| Q3 24 | — | -1633.5% | ||
| Q2 24 | — | -1854.2% | ||
| Q1 24 | — | -26030.8% |
| Q4 25 | — | -67764.2% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -7753.4% | ||
| Q1 25 | — | -7740.4% | ||
| Q4 24 | — | -4007.8% | ||
| Q3 24 | — | -1320.0% | ||
| Q2 24 | — | -1434.8% | ||
| Q1 24 | — | -21030.8% |
| Q4 25 | — | $-1.23 | ||
| Q3 25 | — | $-1.01 | ||
| Q2 25 | — | $-0.85 | ||
| Q1 25 | — | $-0.81 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | — | $-0.64 | ||
| Q2 24 | — | $-0.54 | ||
| Q1 24 | — | $-0.56 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
